The standard of care in BRCA1/2 mutation-associated ovarian cancers is platinum-based chemotherapy (cisplatin, carboplatin) as first line treatment, with poly (ADP-ribose) polymerase inhibitors (PARPi) used increasingly in both the maintenance and metastatic settings. Here, BRCA1 is linked to ovarian carcinoma.